Welcome to our dedicated page for GLOBUS MEDICAL SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Globus Medical filings document formal disclosures for a medical device company focused on musculoskeletal solutions and enabling technologies. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary sales information, financial guidance and related press releases covering net sales, earnings measures, cash flow and segment commentary.
The company’s proxy materials cover board elections, governance practices, executive compensation, equity awards and annual meeting matters. Other current reports document leadership transitions, director departures and related governance events, tying the filing record to Globus Medical’s operating performance, management structure and public-company reporting obligations.
GLOBUS MEDICAL INC (GMED) director Stephen T. Zarrilli reported an option exercise and same-day stock sale. He exercised 25,000 stock options for Class A Common Stock at an exercise price of $53.27 per share, then sold 25,000 shares of Class A Common Stock at a weighted average price of $87.0386 per share in multiple transactions. The options exercised were fully vested and, after the exercise, the reported option position in this grant was 0 shares.
GLOBUS MEDICAL INC (GMED) received a Rule 144 notice for a proposed sale of restricted or control securities. A director, Stephen T. Zarrilli, plans to sell 25,000 shares of common stock through Raymond James & Associates on the NYSE, with an indicated aggregate value of $2,176,000.00. The shares are to be issued via a cashless option exercise with the issuer as of 08/18/2026.
Globus Medical, Inc. reported higher net sales of $789,612 (in thousands) for the quarter ended June 30, 2026 and $1,549,466 (in thousands) for the first half of 2026. Operating income was $182,432 and $332,820 (in thousands), supported by lower cost of sales, acquisition-related and restructuring expenses.
Net income was $151,569 for the quarter and $275,871 (in thousands) year-to-date, with diluted EPS of $1.10 and $2.00, respectively. Prior-year results included a bargain purchase gain of $110,561 (in thousands) from the Nevro acquisition versus $1,118 (in thousands) recognized in 2026.
Cash and cash equivalents totaled $507,745 (in thousands), alongside short-term marketable securities of $87,397 (in thousands) and long-term marketable securities of $245,358 (in thousands). Operating activities generated $412,105 (in thousands) of cash in the first half. The company repurchased 1.6 million Class A shares for $136.1 million under its $500.0 million authorization and had no outstanding borrowings under its $400.0 million revolving credit facility or 0.375% senior convertible notes. Litigation reserves included a previously recorded $43.1 million provision for the Pimenta matter, while other significant cases continue without additional accruals beyond legal fees.
Globus Medical reported second quarter 2026 results with worldwide net sales of $789.6 million, up 5.9% year over year, or 5.6% on a constant currency basis. U.S. net sales grew 3.0%, while international net sales increased 18.0% as reported and 16.2% on a constant currency basis, supported by growth in US Spine and International Spine.
GAAP net income for the quarter was $151.6 million, and GAAP diluted EPS was $1.10, down 26.2% from the prior-year period primarily because the prior year included a $110.5 million bargain purchase gain related to the Nevro acquisition. On a non-GAAP basis, diluted EPS rose 55.8% to $1.34, and Adjusted EBITDA reached $279,839 (in thousands), or 35.4% of net sales, alongside 200 basis points of adjusted gross margin expansion.
For the first six months of 2026, total net sales grew 15.3% year over year. Net cash provided by operating activities was $412,105 (in thousands), supporting free cash flow of $339,322 (in thousands) and total cash, cash equivalents and marketable securities of $840,500 (in thousands). The company reaffirmed 2026 revenue guidance of $3.18–$3.22 billion and raised its non-GAAP fully diluted EPS outlook to $4.95–$5.05 from $4.70–$4.80.
Globus Medical Inc. director David D. Davidar reported a bona fide gift of 2,500 shares of Class A Common Stock on July 27, 2026, at $0.00 per share. After the gift, he directly holds 507,675 shares and has indirect ownership of 165,967 shares held in the Davidar Family Irrevocable Trust U/A 8/6/09 for the benefit of his spouse and children, with his spouse serving as trustee. The filing indicates this transaction was not made under a Rule 10b5-1 trading plan.
Globus Medical director David D. Davidar reported an exercise-and-sell transaction in Class A common stock. He exercised stock options for 25,000 shares at $26.27 per share and sold 25,000 shares in an open-market transaction at a weighted average price of $80.7629 per share.
Following these moves, Davidar directly holds 510,175 shares of Class A common stock. In addition, a family irrevocable trust established on August 6, 2009 holds 165,967 shares for the benefit of his spouse and children, with his spouse serving as trustee.
Globus Medical director Ann D. Rhoads exercised stock options to acquire 25,000 shares of Class A Common Stock at $26.27 per share. These options were granted on January 30, 2017 and were fully vested at exercise. Following the transaction, she directly owns 40,384 shares, and this filing shows no related share sales.
Globus Medical, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved an amendment to the 2021 Equity Incentive Plan to add 1,000,000 additional shares, bringing the total shares authorized for issuance under the plan to 12,000,000 Class A common shares.
The amendment also raised the limit on shares that may be issued as incentive stock options to 12,000,000. Stockholders elected two Class II directors to serve until the 2029 annual meeting, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approved 2025 executive compensation on an advisory basis.
Globus Medical, Inc. reported sharply higher quarterly results for the three months ended March 31, 2026. Net sales rose to $759.9 million from $598.1 million a year earlier, while net income increased to $124.3 million from $75.5 million. Diluted earnings per share improved to $0.90 from $0.54.
Growth came from both U.S. and international markets and reflects the integration of the 2025 Nevro acquisition, which contributed $82.7 million in revenue. The company generated $202.4 million in cash from operating activities, maintained a strong cash and investments position, and recorded ongoing restructuring and acquisition-related costs while continuing to invest in R&D and enabling technologies.